morethistreatmentont
UP,HADA
PEANUTBUTTERAND
RATIO
LifewithNMOSDis Important Safety
InformationthoricknfENSPRYNG helpsbyreducingtheriskof
relapseinadultswith NMOSD,
whethertheyweretreatmentnaiveor
treated.
ENSPRYNG isthefirstandonly
FDA-approved anti-IL-6receptor
monoclonal antibodyforAQP4-
Unlikeothertreatments,ENSPRYNG blocks
theIL-6receptor,allowingformodulationofthe
immunesystemtoaddresskeydriversof
‘TheprecisemechanismbywhichENSPRYNGexertstherapeutic
effectsinNMOSDisunknown.
levelsareelevatedin
andbeindicativeof
duringa2-yearfollow-up,higher
baselineIL-6levelscorrelatedwith
riskofclinicalrelapseand
BytargetingIL-6signaling,
ENSPRYNG isthoughttohelp
decreaseinflammation
permeabilitv. andastrocvteiniurv
ofAQP4-lqG(+)
ENSPRYNG hasawell-studied
safetyprofilewithamedian
exposure of5
TheratesofseriousAEsweresimilarbetween
ENSPRYNG andplacebointwo3
clinicalViewinbrowser
PrescribingInformation
ImportantSafetyInformation
DULLMOMENTS SUCHABADTHING
Indication
ENSPRYNG isindicated
forthetreatmentof
neuromyelitis optica
spectrumdisorder
(NMOSD)inadultpatients
are
(AQP4)antibodypositive.
Contraindications
ENSPRYNG is
contraindicated inpatients
withaknown
hypersensitivity to
satralizumab oranyofthe
inactiveingredients,an
activehepatitisBinfection,
oractiveoruntreated
latenttuberculosis.
Warningsand
Precautions
Infections
Anincreasedriskof
infections,including
seriousandpotentially
fatalinfections,hasbeen
observedinpatie
treatedwithIL-6receptor
antagonists, including
Themost
reportedinarandomized
Clinicaltrialofpatients
treatedwithENSPRYNG
whowerenotonother
chronic
immunosuppressant
therapies,andthat
occurredmoreoftenthan
inpatientsreceiving
placebo,were
nasopharyngitis (12%)
andcellulitis(10%).The
mostcommoninfectionsin
patientswhowereonan
additionalconcurrent
immunosuppressant, and
thatoccurredmoreoften
thaninpatientsreceiving
placebo,were
nasopharyngitis (31%),
upperrespiratoryinfection
(19%),andpharyngitis
(12%).DelayENSPRYNG
administration inpatients
withanactiveinfection,
includinglocalized
infections.
infe
HepatitisBVirus(HBV)
Reactivation
RiskofHBVreactivation
hasbeenobservedwith
otherimmunosuppressant
therapies.Patientswith
chronicHBVir
wereexcludedfrom
Clinicaltrials.PerformHBV
inallpatients
beforeinitiation
treatmentwitt
ENSPRYNG. Donot
administerENSPRYNG to
patientswithactive
hepatitis.Forpatientswho
arechroniccarriersof
HBV[HBsAg+]orare
negativeforHBsAgand
positiveforHBcore
antibody[HBcAb+],
consultliverdisease
expertsbeforestartina
andduringtreatmentwith
ENSPRYNG.
Tuberculosis
Tuberculosis hasoccurred
inpatientstreatedwith
otherreceptor
Patients
shouldbeevaluatedfor
tuberculosis riskfactors
andtestedforla
infectionpriortoinitiating
ENSPRYNG. Consider
anti-tuberculosis therapy
priortoinitiationof
ENSPRYNG inpatients
withahistoryoflatentor
activetuberculosis in
whomanadequatecourse
oftreatmentcannotbe
confirmed,andforpatients
withanegativetestfor
latenttuberculosis but
riskfactorsfor
tuberculosis infection
ImportantSafety
Information continuec
belowWHENITCOMESTOTREATINGAQP4-IgG(+)
to
infections
reportec
keydrivers
WATCHMOAVIDEONMOSD.ou}
resolvedJOPlacebo(n=32)
NGexposureof5yearsinSAkuraMo
onincludedpatientswhoreceivedatleast1do:
andincludedAQP4-seropositive and
Getyourpatientsstartedtoday!
ofcommercialpatientsnationwidehave
unrestrictedfirst-linecoveragefor
ENSPRYNG-no needforpatientstofailother
Beyondroutinevaccinations," noadditional
vaccinesarerequiredbeforestarting
ENSPRYNG. Afterpropertrainingbya
healthcareprovider,patientscanstartself-
administering ENSPRYNG athomeoronthe
ugcoveragepoliciescanchange,pleasecheckwiththe
directlytoconfirmcoverageforindividualpatients.
currentasofNovember2024.tOC
rdingtoimmunizationguidelines,allimmunizationsshould
nisteredatleast4weekspriortoinitiationofENSPRYNGf
asand
Embrace theordinary
withENSPRYNG
CONNECTWITHAREP
AEs=adverseevents;AQP4=aquaporin-4; BBB=blood-brainbarrier;
FDA=FoodandDrugAdministration;lgG=immunoglobulin G;
|L-6=interleukin-6; MOA=mechanism ofaction;SPRYNn=41)Placebo(n=42)
lledpatients
ahel
VIEWSAFETYDATA
HBV
rmcoverage
asofNovemb
whereverpossible.atleast?
Adr
MOA=
tis di
ckingindividual
andvouroffice
ntforserviceor
cestopatients
Important SafetyInformation
Tuberculosis (cont’d)
Consultinfectiousdiseaseexpertsregardingwhetherinitiatinganti-tuberculosis
therapyisappropriatebeforestartingtreatment.Patientsshouldbemonitoredfor
thedevelopment ofsignsandsymptomsoftuberculosiswithENSPRYNG, evenif
initialtuberculosis testingisnegative.
Vaccinations
Liveorlive-attenuated vaccinesshouldnotbegivenconcurrently withENSPRYNG
becauseclinicalsafetyhasnotbeenestablished.Administerallimmunizations
accordingtoimmunization guidelinesatleast4weekspriortoinitiationof
ENSPRYNG forliveorlive-attenuated vaccinesand,wheneverpossible,atleast2
priortoinitiationofENSPRYNG fornon-livevaccines.
ElevatedLiverEnzymes
Mildandmoderateelevationsofliverenzymeshavebeenobservedinpatients
treatedwithENSPRYNG atahigherincidencethaninpatientsreceivingplacebo
ALTandASTlevelsshouldbemonitoredevery4weeksforthefirst3monthsof
treatment,followedbyevery3monthsforoneyear,andthereafter,asclinically
indicated.
Decreased Neutrophil Counts
DecreasesinneutrophilcountswereobservedinpatientstreatedwithENSPRYNG
atahigherincidencethanplacebo.Neutrophilcountsshouldbemonitored4to8
weeksafterinitiationoftherapy,andthereafteratregularclinicallydetermined
intervals.
Hypersensitivity Reactions
Hypersensitivity reactions,includingrash,urticaria,andfatalanaphylaxis, have
occurredwithotherIL-6receptorantagonists.
UseinSpecificPopulations
Pregnancy
Pregnancy ExposureRegistry
Thereisapregnancyexposureregistrythatmonitorspregnancyoutcomesin
womenexposedtoENSPRYNG duringpregnancy.Healthcareprovidersare
encouragedtoregisterpatientsandpregnantwomenareencouragedtoregister
themselvesbycalling1-833-277-9338.
Therearenoadequatedataonthedevelopmental riskassociatedwiththeuseof
ENSPRYNG inpregnantwomen.Inananimalreproduction study,noadverse
effectsonmaternalanimalsorfetaldevelopment wereobservedinpregnant
monkeysandtheiroffspring,withadministration ofENSPRYNG atdosesupto50
mg/kg/week. IntheU.S.generalpopulation,theestimatedbackgroundriskof
majorbirthdefectandmiscarriageinclinicallyrecognizedpregnancies is2
and15—20%,respectively. Theestimatedbackgroundriskofmajorbirthdefects
actation
NoinformationisavailableonthepresenceofENSPRYNG inhumanmilk,the
effectsofENSPRYNG onthebreastfedinfant,ortheeffectsofENSPRYNG on
milkproduction.ENSPRYNG wasexcretedinthemilkoflactatingmonkeys
administered ENSPRYNG throughoutpregnancy.Humanisexcretedinhuman
milkandthepotentialforabsorptionintheinfantisunknown.Thedevelopmental
andhealthbenefitsofbreastfeeding shouldbeconsideredalongwiththemother’s
clinicalneedforENSPRYNG andanypotentialadverseeffectsonthebreastfed
infantfromENSPRYNG orfromtheunderlyingmaternalcondition.
PediatricUse
Safetyandeffectiveness inpediatricpatientshavenotbeenestablished.
GeriatricUse
ClinicalstudiesofENSPRYNG didnotincludesufficientnumbersofpatientsaged
65yearsandoldertodeterminewhethertheyresponddifferentlyfromyounger
patients.However,populationpharmacokinetic analysesinpatientswithNUOSD
didnotshowthatageaffectedthepharmacokinetics ofENSPRYNG. Ingeneral,
cautionshouldbeusedwhendosingtheelderly,reflectingthegreaterfrequencyof
decreasedhepatic,renal,orcardiacfunction,andofconcomitant diseasesorother
drugtherapy.
MostCommonAdverseReactions
Themostcommonadversereactions(215%ineithertrial)werenasopharyngitis
(31%),headache(27%),upperrespiratorytractinfection(19%),rash(17%),
arthralgia(17%),extremitypain(15%),gastritis(15%),fatigue(15%),andnausea
(15%).
YoumayreportsideeffectstotheFDAat(800)FDA-1088or
www.fda.gov/medwatch. YoumayalsoreportsideeffectstoGenentechat
835-9555.
Foradditionalsafetyinformation,pleaseseethefullPrescribingInformationand
MedicationGuide.
Genentech
ContactUs
commercialemailisbroughttoyoubyGenentechUSA,Inc.
emailisintendedforUSresidentsonly
©GenentechUSA.Inc.Allreserved.
JSA,Inc.1DNAWaySouthSanFrancisco,CA94080-4990weeks
riagefortheindicatedpopulationisur
PrivacyPolicyTermsandConditions Unsubscribe